Loading
Principal investigator of ToGA, the trial that made trastuzumab standard in HER2-positive gastric cancer, and a founder of Korean phase 1 oncology.
Yung-Jue Bang is Professor Emeritus of Internal Medicine at the Seoul National University Cancer Research Institute and Seoul National University Hospital. He was principal investigator of ToGA, the trial that made trastuzumab standard in HER2-positive advanced gastric cancer, and a founder of Korean phase 1 oncology, leading a long series of first-in-human and phase 1 studies including early testing of PD-1 antibodies and PARP inhibitors in gastric cancer. His publications include the ToGA trial of trastuzumab with chemotherapy against chemotherapy alone in HER2-positive gastric or gastro-oesophageal junction cancer. He mentored much of Korea's medical oncology leadership.
Patients with newly diagnosed advanced stomach cancer should now have Claudin 18.2 tested alongside HER2, PD-L1 and mismatch repair, because roughly a third will be eligible for zolbetuximab, which adds about three months of median survival. The main practical problem is nausea and vomiting during infusions, which needs aggressive prophylaxis. How to sequence or combine it with immunotherapy in PD-L1-positive tumours is unresolved.
ToGA made gastric cancer the second disease treated by HER2 status and introduced gastric-specific HER2 scoring. It is the base on which trastuzumab deruxtecan and pembrolizumab combinations in HER2-positive gastric cancer have built.
Shares ToGA, Trastuzumab, HER2, Gastric & gastro-oesophageal junction cancer.
Shares Seoul National University Hospital, Gastric & gastro-oesophageal junction cancer.
Shares ToGA, SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer, HER2, Gastric & gastro-oesophageal junction cancer.
Shares Seoul National University Hospital, Gastric & gastro-oesophageal junction cancer.
Shares Trastuzumab, HER2, PD-1, Gastric & gastro-oesophageal junction cancer.
Shares ToGA (Bang 2010): trastuzumab with chemotherapy for HER2-positive advanced gastric cancer, Trastuzumab, HER2.
Shares Trastuzumab, HER2, PD-1, Gastric & gastro-oesophageal junction cancer.
Shares SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer, PD-1, Gastric & gastro-oesophageal junction cancer.